RxGuide Editorial Team

Dr. Sarah Chen is a Board-Certified Pharmacotherapy Specialist (BCPS) with over twelve years of clinical experience in hospital pharmacy and ambulatory care. She completed her Doctor of Pharmacy at the University of California, San Francisco, followed by a PGY-1 pharmacy practice residency at UCSF Medical Center and a PGY-2 specialty residency in cardiology at Stanford Health Care. Dr. Chen has authored more than 40 peer-reviewed articles and patient-education materials covering cardiovascular medications, GLP-1 receptor agonists, and diabetes pharmacotherapy. She joined RxGuide in 2023 to lead the clinical content team, focusing on making complex pharmacology accessible to patients and caregivers.

James Okafor is a Registered Pharmacist with fifteen years of experience spanning retail pharmacy, pharmacy benefit management (PBM), and health policy. He holds a Bachelor of Science in Pharmacy from Howard University and an MBA with a concentration in healthcare management from Johns Hopkins Carey Business School. James spent eight years as a clinical pharmacist at CVS Health and four years as a pharmacy benefit analyst at a national PBM, giving him deep expertise in formulary design, drug pricing, and patient cost-sharing structures. At RxGuide, he leads coverage of prescription drug costs, savings programs, and the economics of the U.S. pharmaceutical supply chain.

Dr. Priya Nair is a board-certified internist and Fellow of the American College of Physicians (FACP) with clinical expertise in endocrinology, metabolic disease, and preventive cardiology. She received her medical degree from the University of Michigan Medical School and completed her internal medicine residency at Massachusetts General Hospital. Dr. Nair maintains an active clinical practice and serves as a medical reviewer for RxGuide, ensuring that all drug information and health articles meet the standards of current clinical practice guidelines. She has a particular focus on GLP-1 pharmacotherapy, insulin management, and cardiovascular risk reduction in patients with type 2 diabetes.

Dr. David Kim is a Board-Certified Cardiology Pharmacist (BCCP) with specialized expertise in cardiovascular pharmacotherapy and drug interaction assessment. He completed his PharmD at the University of Washington School of Pharmacy and a cardiology pharmacy residency at the Cleveland Clinic. Dr. Kim has over a decade of experience reviewing drug interaction databases and clinical pharmacology literature. At RxGuide, he serves as the primary reviewer for drug interaction content, drug comparison pages, and articles covering cardiovascular and lipid-lowering medications. He is a member of the American College of Clinical Pharmacy (ACCP) and the Heart Failure Society of America (HFSA).

Dr. Margaret Liu is a Professor of Medicine and attending cardiologist at Penn Medicine, where she directs the Preventive Cardiology program. She holds an MD from Johns Hopkins and a PhD in cardiovascular pharmacology from the University of Pennsylvania. Dr. Liu has published over 80 peer-reviewed papers on lipid-lowering therapy, statin safety, and cardiovascular risk reduction. She advises RxGuide on the accuracy and clinical currency of all cardiovascular drug content.

Dr. Rafael Morales is a Board-Certified Ambulatory Care Pharmacist (BCACP) and Certified Diabetes Educator (CDE) at Mayo Clinic's Department of Endocrinology. He completed his PharmD at the University of Texas at Austin and an endocrinology specialty residency at Mayo Clinic. Dr. Morales has co-authored clinical practice guidelines on GLP-1 therapy and serves on the American Diabetes Association's pharmacy advisory panel. He oversees RxGuide's diabetes and metabolic disease content for clinical accuracy.

Dr. Anita Patel is a physician-researcher at the Harvard T.H. Chan School of Public Health, where she studies pharmaceutical pricing policy, drug affordability, and the impact of PBM practices on patient out-of-pocket costs. She holds an MD from Yale School of Medicine and an MPH in health policy from Harvard. Dr. Patel's research has been cited in Congressional testimony on drug pricing reform and published in The New England Journal of Medicine, JAMA, and Health Affairs. She advises RxGuide on the accuracy and methodology of all drug cost and pricing content.